{
  "meta": {
    "title": "00014_Mid_Day_Module_Medicine-3",
    "url": "https://brainandscalpel.vercel.app/00014-mid-day-module-medicine-3-27f65a7d.html",
    "scrapedAt": "2025-11-29T18:11:50.351Z"
  },
  "questions": [
    {
      "id": 54031,
      "choices": [
        {
          "id": 215593,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication </span></span></span></p>"
        },
        {
          "id": 215594,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin A intoxication </span></span></span></p>"
        },
        {
          "id": 215595,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis </span></span></span></p>"
        },
        {
          "id": 215596,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-small cell lung cancer (NSCLC)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following conditions causing hypercalcemia is least likely to respond to glucocorticoid therapy?&nbsp;</span></span></span></p>",
      "unique_key": "Q1522890",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927009,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Non-small cell lung cancer (NSCLC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucocorticoids work by reducing the production of 1,25-dihydroxyvitamin D (calcitriol) by activated macrophages and decreasing intestinal calcium absorption. They are effective in treating hypercalcemia caused by:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Excess vitamin D leads to increased intestinal calcium absorption,&nbsp;which can be countered by glucocorticoids.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin A intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids can counteract the bone resorption caused by excess vitamin A.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Activated macrophages in granulomas produce excess calcitriol,&nbsp;and glucocorticoids reduce this production.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, glucocorticoids are not typically effective in treating hypercalcemia caused by <strong>non-small cell lung cancer (NSCLC)</strong>. This type of hypercalcemia is usually due to the production of parathyroid hormone-related protein (PTHrP) by the tumor, which glucocorticoids do not inhibit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are a standard treatment for this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin A intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are effective in treating hypercalcemia related to vitamin A intoxication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are a first-line treatment for hypercalcemia caused by sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The condition causing hypercalcemia that is least likely to respond to glucocorticoid therapy is <strong>non-small cell lung cancer (NSCLC)</strong>.</span></span></p>",
      "correct_choice_id": 215596,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54032,
      "choices": [
        {
          "id": 215597,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Fluids</span></span></p>"
        },
        {
          "id": 215598,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">s.c Denosumab</span></span></p>"
        },
        {
          "id": 215599,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Zoledronic acid </span></span></span></p>"
        },
        {
          "id": 215600,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Calcitonin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with breast cancer presents with dehydration and a serum calcium of 17 mg/dL. Which of the following is not a useful therapy?</span></span></p>",
      "unique_key": "Q4081590",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927010,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) IV Calcitonin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While calcitonin can initially lower serum calcium levels, its effect is transient due to tachyphylaxis (rapidly diminishing response to repeated doses). In a case of severe hypercalcemia (calcium &gt;14 mg/dL), such as in this patient with breast cancer, more potent and longer-lasting therapies are required.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. IV Fluids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Aggressive hydration with isotonic saline is essential to restore intravascular volume and promote renal calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. s.c Denosumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Denosumab,&nbsp;a monoclonal antibody targeting RANKL,&nbsp;is a potent inhibitor of osteoclast activity and bone resorption,&nbsp;making it effective in malignancy-associated hypercalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. IV Zoledronic Acid:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Zoledronic acid,&nbsp;a bisphosphonate,&nbsp;is another potent inhibitor of bone resorption and is commonly used in the management of hypercalcemia of malignancy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-184606.jpg\" style=\"height:596px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-184633.jpg\" style=\"height:451px; width:1000px\" /></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with severe hypercalcemia due to malignancy, <strong>IV Calcitonin</strong> is not as useful due to its transient effect and development of tachyphylaxis.</span></span></span></p>",
      "correct_choice_id": 215600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54033,
      "choices": [
        {
          "id": 215601,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hyperparathyroidism</span></span></p>"
        },
        {
          "id": 215602,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milk-alkali syndrome</span></span></p>"
        },
        {
          "id": 215603,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
        },
        {
          "id": 215604,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of osteoporosis presents with fatigue, nausea, and polyuria. Labs reveal hypercalcemia, metabolic alkalosis, and elevated creatinine. Which of the following is the most likely cause of her symptoms?</span></span></p>",
      "unique_key": "Q5055399",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927011,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Milk-alkali syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of hypercalcemia, metabolic alkalosis, and renal failure in this patient is highly suggestive of milk-alkali syndrome. This condition is caused by excessive intake of calcium and absorbable alkali (milk/calcium carbonate), which is common in osteoporosis.<br />\r\nRisk is higher if the patient has co-existing renal failure (due to reduced calcium excretion).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Primary hyperparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While it can cause hypercalcemia,&nbsp;it is not typically associated with metabolic alkalosis and renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Can cause hypercalcemia but is usually associated with granulomatous inflammation and elevated 1,25-dihydroxyvitamin D levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While it can cause hypercalcemia,&nbsp;it is not usually associated with metabolic alkalosis and renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most likely cause of hypercalcemia, metabolic alkalosis, and renal impairment in an elderly woman with osteoporosis is <strong>milk-alkali syndrome</strong>.</span></span></p>",
      "correct_choice_id": 215602,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54035,
      "choices": [
        {
          "id": 215609,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudopseudohypoparathyroidism (PPHP) </span></span></span></p>"
        },
        {
          "id": 215610,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 1A (PHP1A) </span></span></span></p>"
        },
        {
          "id": 215611,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 1B (PHP1B) </span></span></span></p>"
        },
        {
          "id": 215612,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 2 (PHP2)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old child presents with short stature, round face, obesity, shortened fourth and fifth metacarpals, hypocalcemia, and hyperphosphatemia. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q1494916",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927012,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Pseudohypoparathyroidism type 1A (PHP1A)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The child&#39;s presentation is characteristic of Albright&#39;s hereditary osteodystrophy (AHO), which is a key feature of PHP1A. AHO includes short stature, round face, obesity, brachydactyly (shortened metacarpals/metatarsals), and sometimes intellectual disability. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The laboratory findings of hypocalcemia and hyperphosphatemia, along with elevated PTH levels, are consistent with PTH resistance, a hallmark of pseudohypoparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pseudopseudohypoparathyroidism (PPHP):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Individuals with PPHP have AHO features but normal calcium,&nbsp;phosphate,&nbsp;and PTH levels.&nbsp;They do not exhibit hormone resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pseudohypoparathyroidism type 1B (PHP1B):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While PHP1B also presents with hypocalcemia and hyperphosphatemia,&nbsp;it is less likely to be associated with the full spectrum of AHO features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pseudohypoparathyroidism type 2 (PHP2):</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;PHP2 is characterized by hypocalcemia and hyperphosphatemia with normal urinary cAMP response to PTH,&nbsp;but it does not typically present with AHO features.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-190718.jpg\" style=\"height:499px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The child&#39;s presentation with short stature, round face, obesity, shortened fourth and fifth metacarpals, hypocalcemia, and hyperphosphatemia is characteristic of Albright&#39;s hereditary osteodystrophy (AHO), which is associated with PHP1A.</span></span></span></p>",
      "correct_choice_id": 215610,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54038,
      "choices": [
        {
          "id": 215621,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zoledronate </span></span></span></p>"
        },
        {
          "id": 215622,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate </span></span></span></p>"
        },
        {
          "id": 215623,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab </span></span></span></p>"
        },
        {
          "id": 215624,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient had a hip fracture and was started on a bone protective agent. However, after 3 years of use, the patient lost follow-up and stopped therapy. Within 3 months of stopping treatment, the patient developed a new vertebral fracture. What is the drug that was likely given initially and stopped?</span></span></span></p>",
      "unique_key": "Q2972485",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927013,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Denosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab is a monoclonal antibody that inhibits RANKL, a key factor in osteoclast formation and function. While it is effective in reducing bone resorption and increasing bone density, its effects are rapidly reversible upon discontinuation. When denosumab is stopped, there can be a rebound increase in bone turnover and a significant loss of bone density, leading to an increased risk of fractures, particularly vertebral fractures, within a short period.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Zoledronate and Option B. Alendronate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are bisphosphonates, which have a longer-lasting effect on bone remodeling than denosumab. While there can be a gradual loss of bone density after discontinuing bisphosphonates, it is not as rapid or dramatic as the rebound effect seen with denosumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a selective estrogen receptor modulator (SERM) with a milder effect on bone density compared to bisphosphonates and denosumab. Its discontinuation is not typically associated with a rapid increase in fracture risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab is associated with a rapid rebound increase in bone turnover and risk of fractures upon discontinuation, which explains the new vertebral fracture within three months of stopping the drug.</span></span></span></p>",
      "correct_choice_id": 215623,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54039,
      "choices": [
        {
          "id": 215625,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strontium ranelate </span></span></span></p>"
        },
        {
          "id": 215626,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate </span></span></span></p>"
        },
        {
          "id": 215627,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Romosozumab </span></span></span></p>"
        },
        {
          "id": 215628,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old lady presented with a Colles&#39; fracture. She has diabetes and suffered from an MI 2 years ago and a stroke a year ago. Which of the following drugs would be the most appropriate for her osteoporosis treatment?</span></span></p>",
      "unique_key": "Q8953429",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927014,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Alendronate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate is a bisphosphonate, a class of drugs that are the first-line treatment for osteoporosis in most patients. It has been shown to reduce the risk of both vertebral and non-vertebral fractures, including Colles&#39; fractures. It is well-tolerated in most patients and has a good safety profile.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Strontium ranelate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Not available in the US and has a potential risk of cardiovascular events, which would be a concern in this patient with a history of MI and stroke.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Romosozumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While effective in reducing fractures, it has a higher cost and is usually reserved for patients with severe osteoporosis who have failed other treatments. Its safety profile in patients with cardiovascular disease is not yet fully established.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a SERM that is primarily effective in reducing vertebral fractures and has limited data on preventing non-vertebral fractures like Colles&#39; fractures. Additionally, it carries a risk of thromboembolic events which might be a concern in this patient (but note that Raloxifene does not increase CV risk like HRT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fracture reduction data:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-192229.jpg\" style=\"height:446px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate is effective for reducing the risk of fractures and is generally well-tolerated, making it the most appropriate choice for a patient with a history of cardiovascular events and a Colles&#39; fracture.</span></span></span></p>",
      "correct_choice_id": 215626,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54041,
      "choices": [
        {
          "id": 215633,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen</span></span></span></p>"
        },
        {
          "id": 215634,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Equine estrogen with medroxyprogesterone </span></span></span></p>"
        },
        {
          "id": 215635,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene </span></span></span></p>"
        },
        {
          "id": 215636,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old depressed woman presents with a T-score of -2.8 on DEXA scan and severe hot flashes. She has a past history of hysterectomy 6 years ago. Which of the following would be the most suitable treatment for this patient to prevent fractures?</span></span></p>",
      "unique_key": "Q1179618",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927015,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Transdermal estrogen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen is the most suitable option because it addresses both the patient&#39;s osteoporosis (T-score -2.8) and severe hot flashes, a common symptom of menopause. Estrogen therapy is effective in preventing bone loss and reducing fracture risk in postmenopausal women, while also providing relief from menopausal symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since the patient has undergone a hysterectomy, she does not require progestin to protect the endometrium, making estrogen-only therapy the preferred choice.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risks and benefits of estrogen-progestin combinations is shown -</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-192756.jpg\" style=\"height:404px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Equine estrogen with medroxyprogesterone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this combination therapy is effective for osteoporosis and hot flashes, it is not necessary for women who have had a hysterectomy as it includes progestin, which is used to protect the endometrium in women with a uterus. Addition of progestin can potentially increase the risk of breast cancer as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a selective estrogen receptor modulator (SERM) that can be used to prevent osteoporosis. However, it can worsen hot flashes and is not the ideal choice for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Teriparatide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Teriparatide is an anabolic agent that stimulates bone formation. While effective for osteoporosis, it does not address menopausal symptoms and is generally reserved for patients with severe osteoporosis who have failed other treatments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen is effective for both osteoporosis and severe hot flashes, and since the patient has had a hysterectomy, she does not need progestin.</span></span></p>",
      "correct_choice_id": 215633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6661,
      "choices": [
        {
          "id": 26613,
          "text": "<p><span style=\"font-size:12.0pt;\">Reteplase</span></p>"
        },
        {
          "id": 26614,
          "text": "<p><span style=\"font-size:12.0pt;\">Tirofiban</span></p>"
        },
        {
          "id": 26615,
          "text": "<p><span style=\"font-size:12.0pt;\">Enoxaparin</span></p>"
        },
        {
          "id": 26616,
          "text": "<p><span style=\"font-size:12.0pt;\">Emergent coronary angiography</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old woman with acute chest pain for the last 3 hours. Aspirin and clopidogrel was given in the ambulance. ECG is taken in ER and shown below. What is the next step?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-171044.png\" alt=\"\" width=\"400\" height=\"204\"></span></p>",
      "unique_key": "Q1878728",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927016,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>C) Enoxaparin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">ECG shows widespread ST segment depression, suggesting a diagnosis of acute coronary syndrome (ACS) without ST-elevation (NSTE-ACS). In patients with suspected NSTE-ACS, early administration of anticoagulation is crucial to prevent further thrombus formation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Reteplase</strong>: This is a thrombolytic agent used in STEMI and not in NSTE-ACS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Tirofiban</strong>: GpIIb/IIIa inhibitor used primarily during PCI under special circumstances.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Emergent Coronary angiography</strong>: While angiography is crucial to confirm the diagnosis and guide further management, immediate anticoagulation with enoxaparin should be initiated first. In this patient with ST depression (a high risk factor), URGENT coronary angiography is optimal (&lt; 24h) rather than immediate (&lt; 2h).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In patients with suspected NSTE-ACS, early administration of enoxaparin is crucial to prevent further thrombus formation while awaiting coronary angiography.</span></p>",
      "correct_choice_id": 26615,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6666,
      "choices": [
        {
          "id": 26633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery bypass grafting (CABG) </span></span></span></p>"
        },
        {
          "id": 26634,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medical therapy without revascularization </span></span></span></p>"
        },
        {
          "id": 26635,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocardial viability testing </span></span></span></p>"
        },
        {
          "id": 26636,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Percutaneous coronary intervention (PCI)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with exertional chest pain and a positive stress test undergoes angiography revealing complex multivessel coronary artery disease (CAD) involving the left main. He has a left ventricular ejection fraction (LVEF) of 42%. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q3897808",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927017,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Coronary artery bypass grafting (CABG)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CABG is the preferred revascularization strategy for patients with complex multivessel CAD, especially involving the left main, and with reduced LVEF. It offers superior survival benefits compared to medical therapy alone or PCI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Medical therapy</span></strong><span style=\"font-size:12.0pt\">: Insufficient for complex CAD and reduced LVEF, carries a higher risk of adverse events. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Viability testing</span></strong><span style=\"font-size:12.0pt\">: Not necessary before revascularization in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PCI</span></strong><span style=\"font-size:12.0pt\">: Less favorable than CABG for complex multivessel disease, especially with left main involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with multivessel coronary artery disease, coronary artery bypass grafting is associated with enhanced survival compared with medical therapy alone.</span></span></span></p>",
      "correct_choice_id": 26633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6754,
      "choices": [
        {
          "id": 26985,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel</span></span></span></p>"
        },
        {
          "id": 26986,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose aspirin </span></span></span></p>"
        },
        {
          "id": 26987,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prasugrel </span></span></span></p>"
        },
        {
          "id": 26988,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with stable angina and aspirin allergy is undergoing lifestyle counseling and antianginal therapy. What is the most appropriate cardioprotective treatment?</span></span></p>",
      "unique_key": "Q7745718",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927018,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Clopidogrel</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is recommended for secondary prevention in patients with stable ischemic heart disease who are intolerant or allergic to aspirin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low-dose aspirin</span></strong><span style=\"font-size:12.0pt\">: Contraindicated due to aspirin allergy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prasugrel</span></strong><span style=\"font-size:12.0pt\"> and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>D. Ticagrelor</strong>: More potent antiplatelet agents, typically used in acute coronary syndrome or after PCI, not as monotherapy for stable angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All patients with stable ischemic heart disease should receive guideline-directed therapies consisting of lifestyle modification, cardioprotective therapy, and antianginal medication.&nbsp;</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with stable ischemic heart disease should receive antiplatelet therapy (low-dose aspirin or clopidogrel in aspirin-intolerant patients) for secondary prevention of cardiovascular events.</span></span></span></p>",
      "correct_choice_id": 26985,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6602,
      "choices": [
        {
          "id": 26377,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 month </span></span></span></p>"
        },
        {
          "id": 26378,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 months </span></span></span></p>"
        },
        {
          "id": 26379,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 months </span></span></span></p>"
        },
        {
          "id": 26380,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">12 months</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with diabetes mellitus received a drug-eluting stent for non-ST elevation acute coronary syndrome (NSTE-ACS). She was started on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the recommended minimum duration of her antiplatelet therapy?</span></span></p>",
      "unique_key": "Q2994818",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927019,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) 12 months</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with diabetes who have received a drug-eluting stent for NSTE-ACS, the recommended minimum duration of DAPT (aspirin plus a P2Y12 inhibitor like clopidogrel) is <strong>12 months</strong>. This is due to the increased risk of stent thrombosis and major adverse cardiovascular events in patients with diabetes compared to those without.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 1 month:</span></strong><span style=\"font-size:12.0pt\"> This duration is too short and would significantly increase the risk of stent thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 3 months:</span></strong><span style=\"font-size:12.0pt\"> While some studies suggest shorter durations may be safe in select patients, the standard recommendation for patients with diabetes is 12 months.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. 6 months:</strong> This is the minimum duration for patients without diabetes who have received a drug-eluting stent for ACS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand the recommended duration of dual antiplatelet therapy in patients with diabetes who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents for acute coronary syndrome. </span></span></span></p>",
      "correct_choice_id": 26380,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6756,
      "choices": [
        {
          "id": 26993,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of clopidogrel </span></span></span></p>"
        },
        {
          "id": 26994,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of isosorbide mononitrate </span></span></span></p>"
        },
        {
          "id": 26995,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography </span></span></span></p>"
        },
        {
          "id": 26996,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise echocardiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 69-year-old man with persistent angina despite maximally tolerated antianginal therapy. He has orthostatic hypotension and current BP and PR are 100/60 mm Hg and 54/min respectively. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q1856672",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927020,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography is the most appropriate step to assess for obstructive coronary artery disease and guide potential revascularization to improve symptoms and quality of life.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Addition of Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated for stable angina without recent revascularization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Addition of Isosorbide mononitrate</span></strong><span style=\"font-size:12.0pt\">: Adding more antianginal medication may not be helpful if the patient is already on maximally tolerated doses. Addition of nitrate in this patient may worsen orthostatic hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise echocardiography</span></strong><span style=\"font-size:12.0pt\">: May provide prognostic information but doesn&#39;t identify lesions for revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the setting of persistent symptoms despite maximally tolerated medical therapy, invasive imaging for revascularization assessment is appropriate to improve symptom status and quality of life.</span></span></span></p>",
      "correct_choice_id": 26995,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19785,
      "choices": [
        {
          "id": 79101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiography </span></span></span></p>"
        },
        {
          "id": 79102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apixaban </span></span></span></p>"
        },
        {
          "id": 79103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Unfractionated heparin </span></span></span></p>"
        },
        {
          "id": 79104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?</span></span></p>",
      "unique_key": "Q4623786",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927021,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Unfractionated heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with acute limb ischemia (ALI). Immediate anticoagulation with unfractionated heparin is crucial to prevent further thrombus propagation while awaiting definitive intervention (angiography).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Angiography</span></strong><span style=\"font-size:12.0pt\">: Essential for diagnosis and planning revascularization, but anticoagulation should be started first. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Apixaban</span></strong><span style=\"font-size:12.0pt\">: Oral anticoagulant, not appropriate in the acute setting of ALI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Not indicated for ALI, which is an arterial problem.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat acute limb ischemia with anticoagulation.</span></span></span></p>",
      "correct_choice_id": 79103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19786,
      "choices": [
        {
          "id": 79105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 79106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
        },
        {
          "id": 79107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propranolol </span></span></span></p>"
        },
        {
          "id": 79108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reassurance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with no medical history presents with frequent, bothersome palpitations that subside with exercise and in the nights. ECG is shown. Echo and baseline lab tests including CBC and TFT are normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-172502.png\" style=\"height:138px; width:300px\" /></span></span></p>",
      "unique_key": "Q2886254",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927022,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Propranolol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has symptomatic premature ventricular contractions (PVCs) that are bothersome. Beta-blockers are the first-line treatment for symptomatic PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential toxicity, not first-line for simple PVCs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: Not helpful for diagnosing PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reassurance</span></strong><span style=\"font-size:12.0pt\">: Not sufficient for bothersome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are the first-line treatment for symptomatic PVCs in patients without structural heart disease.</span></span></span></p>",
      "correct_choice_id": 79107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54145,
      "choices": [
        {
          "id": 216049,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
        },
        {
          "id": 216050,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone </span></span></span></p>"
        },
        {
          "id": 216051,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen per nasal cannula </span></span></span></p>"
        },
        {
          "id": 216052,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent coronary angiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man presents with recurrent chest pain and elevated troponin. ECG is shown. remains in pain despite aspirin, clopidogrel, heparin, and nitroglycerin. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-173300.png\" style=\"height:256px; width:300px\" /></span></span></p>",
      "unique_key": "Q9684555",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927023,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Urgent coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has NSTE-ACS with refractory angina despite medical therapy. Urgent coronary angiography is indicated to identify the culprit lesion and potentially perform revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: May be helpful, but not the immediate priority. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eplerenone</span></strong><span style=\"font-size:12.0pt\">: Indicated in certain post-MI patients, but not the immediate priority for refractory angina. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oxygen per nasal cannula</span></strong><span style=\"font-size:12.0pt\">: Indicated only if the patient is hypoxic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urgent or immediate diagnostic angiography with intent to perform revascularization is indicated in patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability.</span></span></span></p>",
      "correct_choice_id": 216052,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54147,
      "choices": [
        {
          "id": 216057,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 216058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
        },
        {
          "id": 216059,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin </span></span></span></p>"
        },
        {
          "id": 216060,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pramlintide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with type 2 diabetes, hypertension, hyperlipidemia, and aortofemoral bypass surgery 2 years ago has an HbA1c of 7.1%. His current medications are metformin, atenolol, ramipril, amlodipine, aspirin, rivaroxaban, and atorvastatin. Which medication is most appropriate to add for cardiovascular risk reduction?</span></span></p>",
      "unique_key": "Q8365159",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927024,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Liraglutide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP-1 receptor agonists like liraglutide have been shown to reduce cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), which this patient has due to his history of bypass surgery. Liraglutide also promotes weight loss, which can be beneficial for this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Patient is already on rivaroxaban and aspirin. Addition of clopidogrel would not provide any additional benefit and only increase the bleeding risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: No longer recommended for routine use due to lack of benefit and side effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pramlintide</span></strong><span style=\"font-size:12.0pt\">: Amylin analog used for glycemic control, no proven cardiovascular benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are associated with reduced rates of adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, compared with placebo.</span></span></span></p>",
      "correct_choice_id": 216058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54149,
      "choices": [
        {
          "id": 216065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin</span></span></span></p>"
        },
        {
          "id": 216066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
        },
        {
          "id": 216067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin</span></span></span></p>"
        },
        {
          "id": 216068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No changes in management</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 59-year-old man with type 2 diabetes and a history of stroke is on aspirin, metformin, olmesartan, and rosuvastatin. His LDL-C is 66 mg/dL, HDL-C is 28 mg/dL and HbA1c is 6.8%. What additional medication should be considered for CV risk reduction?</span></span></p>",
      "unique_key": "Q1218758",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927025,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Empagliflozin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular events in patients with type 2 diabetes and established ASCVD. They are recommended as part of a comprehensive cardiovascular risk reduction strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ezetimibe</span></strong><span style=\"font-size:12.0pt\">: Not indicated as LDL cholesterol is already well-controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: Can increase HDL but no longer recommended for routine use due to lack of benefit and side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No changes in management</span></strong><span style=\"font-size:12.0pt\">: Inadequate as SGLT2 inhibitors provide additional CV benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors to the treatment regimen for patients with type 2 diabetes and established ASCVD to reduce CV risk.</span></span></span></p>",
      "correct_choice_id": 216065,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54151,
      "choices": [
        {
          "id": 216073,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add amlodipine </span></span></span></p>"
        },
        {
          "id": 216074,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decrease lisinopril dosage </span></span></span></p>"
        },
        {
          "id": 216075,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce isosorbide mononitrate&nbsp;dosage&nbsp;to once daily </span></span></span></p>"
        },
        {
          "id": 216076,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat coronary angiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with CAD and diabetes mellitus experiences worsening angina. He is currently on ramipril, diltiazem, metformin, atorvastatin and isosorbide mononitrate twice daily. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q4464879",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927026,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Reduce isosorbide mononitrate dosage to once daily</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is likely experiencing nitrate tolerance, a common side effect of long-acting nitrates like isosorbide mononitrate. Reducing the frequency to once daily with a nitrate-free interval helps restore nitrate efficacy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding amlodipine</span></strong><span style=\"font-size:12.0pt\">: Not the first-line option when nitrate tolerance is suspected. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreasing lisinopril</span></strong><span style=\"font-size:12.0pt\">: Not indicated as blood pressure is controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat coronary angiography</span></strong><span style=\"font-size:12.0pt\">: Not necessary unless there is a suspicion of new coronary lesions or progression of existing ones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Long-acting nitrates provide a constant level of vasodilation and symptom relief throughout the day, but a nitrate-free interval is required to avoid tolerance.</span></span></span></p>",
      "correct_choice_id": 216075,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54154,
      "choices": [
        {
          "id": 216085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ambulatory ECG monitoring </span></span></span></p>"
        },
        {
          "id": 216086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue flecainide </span></span></span></p>"
        },
        {
          "id": 216087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue metoprolol </span></span></span></p>"
        },
        {
          "id": 216088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise stress testing</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents with inferior STEMI and he is successfully treated with PCI. He has a history of paroxysmal AF and was taking flecainide. He was also started on rivaroxaban, metoprolol, and ramipril post PCI. He is currently asymptomatic and now planned for discharge from the hospital. What is the most appropriate management?</span></span></span></p>",
      "unique_key": "Q8773956",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927027,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Discontinue flecainide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This patient has ischemic heart disease and previously diagnosed paroxysmal atrial fibrillation (AF). Amiodarone, dofetilide, flecainide, propafenone, sotalol, and dronedarone may be used to maintain sinus rhythm in patients with AF. Antiarrhythmic drug selection is guided by the patient&#39;s comorbid conditions and safety considerations. Flecainide is a class IC antiarrhythmic agent and, along with propafenone, is absolutely contraindicated in patients with ischemic heart disease, given the increased risk for ventricular arrhythmias in this population. This patient also has evidence of left ventricular (LV) dysfunction on a post&ndash;myocardial infarction echocardiogram, which may be due to infarcted myocardium and may lead to increased long-term risk for ventricular arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ambulatory ECG monitoring</span></strong><span style=\"font-size:12.0pt\">: Helpful for assessing AF burden but doesn&#39;t address the contraindication of flecainide. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Discontinue metoprolol</span></strong><span style=\"font-size:12.0pt\">: Not ideal as it&#39;s essential for managing ischemic heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise stress testing</span></strong><span style=\"font-size:12.0pt\">: Not recommended immediately post-MI, especially with existing conduction abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IC antiarrhythmics like flecainide are C/I in patients with ischemic heart disease due to an increased risk of ventricular arrhythmias and death. </span></span></span></p>",
      "correct_choice_id": 216086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54158,
      "choices": [
        {
          "id": 216101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 216102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac catheterization</span></span></span></p>"
        },
        {
          "id": 216103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardioversion </span></span></span></p>"
        },
        {
          "id": 216104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old man with a history of hypertension and CAD presents with recurrent atrial flutter. He is on dabigatran, metoprolol, ramipril, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q4144421",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927028,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Catheter ablation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the definitive treatment for typical atrial flutter, with a high success rate (&gt; 95%) and low complication rate. It&#39;s the most appropriate option for this patient with recurrent symptomatic atrial flutter despite rate control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential for toxicity, not the first-line treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cardiac catheterization</span></strong><span style=\"font-size:12.0pt\">: Not needed for treating atrial flutter at this point. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardioversion</span></strong><span style=\"font-size:12.0pt\">: May provide temporary relief but is not definitive treatment in this case where the patient is experiencing recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the best treatment for recurrent typical atrial flutter.</span></span></span></p>",
      "correct_choice_id": 216104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54159,
      "choices": [
        {
          "id": 216105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol </span></span></span></p>"
        },
        {
          "id": 216106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase digoxin </span></span></span></p>"
        },
        {
          "id": 216107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase lisinopril </span></span></span></p>"
        },
        {
          "id": 216108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start Noradrenaline</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 75-year-old woman with ischemic cardiomyopathy presents with progressive dyspnea, edema and confusion. Her medications include low-dose aspirin, furosemide, carvedilol, ramipril, digoxin, and spironolactone. Her BP is 84/52 mm Hg, PR is 118/min, RR is 28/min and SpO2 is 95 in room air. Her reports are shown below. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ALT - 172 U/L, AST - 163 U/L, S. Creatinine - 2.9 mg/dL , S. K - 4.7 mEq/L, S. Na - 132 mEq/L &amp; S. Digoxin - 0.3 ng/mL.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most appropriate initial treatment?</span></span></span></p>",
      "unique_key": "Q5304020",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927029,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Start Nonadrenaline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has cardiogenic shock due to acute decompensated heart failure (ADHF). Noradrenaline (NA), an inotrope, is indicated to improve cardiac output in this scenario. Once NA is added, other inotropes like dobutamine and/or milrinone can be added sequentially to ensure adequate support. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase carvedilol</span></strong><span style=\"font-size:12.0pt\">: Beta-blockers are contraindicated in cardiogenic shock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Increase digoxin</span></strong><span style=\"font-size:12.0pt\">: Not effective in cardiogenic shock and potentially harmful with AKI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase lisinopril</span></strong><span style=\"font-size:12.0pt\">: Afterload reduction may be considered later, but inotropic support is the priority in this patient with cardiogenic shock.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with cardiogenic shock, inotropes such as Noradrenaline, dobutamine or milrinone may be considered to improve cardiac function.</span></span></span></p>",
      "correct_choice_id": 216108,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54160,
      "choices": [
        {
          "id": 216109,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add clopidogrel </span></span></span></p>"
        },
        {
          "id": 216110,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add oral anticoagulation </span></span></span></p>"
        },
        {
          "id": 216111,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue aspirin and begin oral anticoagulation </span></span></span></p>"
        },
        {
          "id": 216112,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No change in therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old asymptomatic woman with CAD, diabetes and hypertension presents with palpitations. ECG shows AF. She is on metoprolol, telmisartan, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q2690057",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927030,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Discontinue aspirin and begin oral anticoagulation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has AF and is at high risk for stroke (CHA2DS2-VASc score of 5). Oral anticoagulation is indicated for stroke prevention. Aspirin should be discontinued as it provides no additional benefit and increases bleeding risk when combined with anticoagulants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated, as the patient has no recent ACS or stent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adding oral anticoagulation without discontinuing aspirin</span></strong><span style=\"font-size:12.0pt\">: Increases bleeding risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No change in therapy</span></strong><span style=\"font-size:12.0pt\">: Inadequate as the patient needs anticoagulation for stroke prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For most patients with high-risk atrial fibrillation and stable coronary artery disease, oral anticoagulation therapy without an antiplatelet agent is sufficient for prevention of both acute coronary syndromes and thromboembolism.</span></span></span></p>",
      "correct_choice_id": 216111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54162,
      "choices": [
        {
          "id": 216117,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ankle-brachial index (ABI) </span></span></span></p>"
        },
        {
          "id": 216118,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lower extremity CT angiography </span></span></span></p>"
        },
        {
          "id": 216119,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Toe-brachial index (TBI) </span></span></span></p>"
        },
        {
          "id": 216120,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with diabetes and PAD has a right foot ulcer and feeble pulses. Ankle Brachial Index (ABI) on the right is 1.65. What is the next step?</span></span></p>",
      "unique_key": "Q6831255",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927031,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Toe-brachial index (TBI)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When the ABI is uninterpretable due to non-compressible vessels (ABI &gt;1.40), the toe-brachial index (TBI) is a reliable alternative to assess for peripheral arterial disease (PAD). A TBI &lt;0.70 indicates significant PAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Exercise ABI</span></strong><span style=\"font-size:12.0pt\">: Not useful when resting ABI is uninterpretable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lower Extremity CT angiography</span></strong><span style=\"font-size:12.0pt\">: Helpful for planning revascularization, but TBI is the more appropriate initial test in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Evaluates for venous disease, not arterial.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Toe-brachial index (TBI) is useful in diagnosing PAD when ankle-brachial index (ABI) is uninterpretable due to non-compressible vessels.</span></span></span></p>",
      "correct_choice_id": 216119,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54163,
      "choices": [
        {
          "id": 216121,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenosine single-photon emission CT </span></span></span></p>"
        },
        {
          "id": 216122,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery calcium scoring </span></span></span></p>"
        },
        {
          "id": 216123,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise electrocardiography </span></span></span></p>"
        },
        {
          "id": 216124,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress echocardiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">52-year-old woman complains of chest tightness after walking for 2-3 km and relieved with rest.&nbsp; Her resting ECG is normal. She is known case of hypertension and dyslipidemia and currently taking ramipril and atorvastatin. What is the most appropriate diagnostic test?</span></span></p>",
      "unique_key": "Q6859475",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927032,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Exercise electrocardiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with a normal resting ECG and the ability to exercise, exercise ECG is the recommended initial test for evaluating suspected coronary artery disease (CAD). It provides valuable information about exercise capacity and ischemic response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adenosine single-photon emission CT</span></strong><span style=\"font-size:12.0pt\">: Reserved for patients who cannot exercise or have uninterpretable ECGs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary artery calcium scoring</span></strong><span style=\"font-size:12.0pt\">: Used for risk stratification in asymptomatic patients especially to know the need for a statin. The patient is already on atorvastatin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stress echocardiography</span></strong><span style=\"font-size:12.0pt\">: Can be considered if exercise ECG is inconclusive. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG is the first-line test for evaluating suspected CAD in patients with typical angina and a normal resting ECG.</span></span></span></p>",
      "correct_choice_id": 216123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54164,
      "choices": [
        {
          "id": 216125,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add carvedilol </span></span></span></p>"
        },
        {
          "id": 216126,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
        },
        {
          "id": 216127,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add digoxin</span></span></span></p>"
        },
        {
          "id": 216128,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRT-D</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with ischemic cardiomyopathy (EF 20%) and NYHA class III heart failure is on maximally tolerated doses of ACE inhibitor, furosemide, and empagliflozin. ECG shows LBBB with a QRS duration of 130 ms. What is the most appropriate additional treatment?</span></span></p>",
      "unique_key": "Q5229798",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927033,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Add carvedilol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are part of guideline-directed medical therapy (GDMT) for HFrEF and sh</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ould be added to the patient&#39;s regimen. While CRT might be considered in the future if symptoms persist despite optimal medical therapy, adding a beta-blocker is the most appropriate initial step.&nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Current GDMT for HFrEF includes ARNi/ACEi or ARB, Beta blockers, MRA and SGLT2i. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add Ivabradine</span></strong><span style=\"font-size:12.0pt\">: Indicated only after maximally tolerated beta-blocker dose. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CRT-D</span></strong><span style=\"font-size:12.0pt\">: Considered if LVEF remains &le;35%, QRS duration &ge;150 ms, and NYHA class II-IV symptoms despite optimal medical therapy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add digoxin</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">: Considered for primary prevention of sudden cardiac death in patients with LVEF &le;35% despite optimal medical therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate beta-blocker therapy in patients with HFrEF who are not already on it, as part of guideline-directed medical therapy.</span></span></span></p>",
      "correct_choice_id": 216125,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54165,
      "choices": [
        {
          "id": 216129,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate endovascular stenting </span></span></span></p>"
        },
        {
          "id": 216130,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate open surgical repair </span></span></span></p>"
        },
        {
          "id": 216131,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV labetalol </span></span></span></p>"
        },
        {
          "id": 216132,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat CT angiography in 12 hours</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old woman presents with acute type B aortic dissection involving the descending thoracic aorta with a maximal aortic diameter of 6.8 cm. Her BP is 173/99 mm Hg and PR is 90/min. What is the most appropriate initial management?</span></span></p>",
      "unique_key": "Q2175334",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927034,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) IV labetalol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In acute type B aortic dissection, the immediate priority is to aggressively control blood pressure and heart rate to limit the propagation of the dissection. IV labetalol is a combined alpha- and beta-blocker that is effective in rapidly reducing blood pressure and heart rate, making it the most appropriate initial management in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While surgery or endovascular stenting may be indicated in the future, they are not the immediate priority. The patient should be stabilized first with medical management before considering invasive interventions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immediate endovascular stenting:</span></strong><span style=\"font-size:12.0pt\"> Endovascular stenting can be used to treat patients with descending aortic aneurysms; however, there is scant evidence to support this as an initial treatment option for aneurysm with dissection. After medical stabilization, thoracic endovascular aortic repair (TEVAR) with stent grafting can be used; typical indications include descending aortic aneurysm diameter greater than 6.0 cm, rapid growth (&gt;0.5 cm/year), or end-organ damage. TEVAR has the advantage over surgical operation of lower morbidity and shorter hospital stay, although there may be complications, including stroke, spinal ischemia, and aortic graft endoleaks. This patient should be treated with stent implantation only after medical stabilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Immediate open surgical repair:</span></strong><span style=\"font-size:12.0pt\"> Open surgical repair of the descending aorta is not recommended in patients with uncomplicated type B aortic dissection because of high rates of morbidity (such as paraplegia) and mortality. This patient has no signs or symptoms of complications that would prompt immediate surgical repair.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat CT angiography in 12 hours:</span></strong><span style=\"font-size:12.0pt\"> Repeat CT angiography at 12 hours is not indicated unless the patient does not stabilize with medical therapy. Serial imaging (usually magnetic resonance angiography) is typically performed in asymptomatic patients at the time of discharge and then periodically in patients who do not have an indication for aneurysmal repair to screen for extension or recurrence of the dissection, aneurysm formation, and leakage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with uncomplicated type B aortic dissection may be initially treated with medical therapy, including &beta;-blockers, sodium nitroprusside, and opioids.</span></span></span></p>",
      "correct_choice_id": 216131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54166,
      "choices": [
        {
          "id": 216133,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel now </span></span></span></p>"
        },
        {
          "id": 216134,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel in 5 months </span></span></span></p>"
        },
        {
          "id": 216135,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel in 11 months </span></span></span></p>"
        },
        {
          "id": 216136,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel and aspirin in 11 months</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 81-year-old woman had a drug-eluting stent (DES) for chronic stable angina 1 month ago. She is currently on aspirin and clopidogrel. She is a known case of hypertension, dyslipidaemia, CKD and peptic ulcer disease and was on medications for the same. She wants to minimize DAPT in view of her age and comorbidities. How long should she continue DAPT?</span></span></p>",
      "unique_key": "Q1428459",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927035,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Discontinue clopidogrel in 5 months</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Guidelines suggest a minimum of 6 months of DAPT after elective DES placement. Given this patient&#39;s high bleeding risk, it is reasonable to discontinue clopidogrel after 6 months (5 additional months) while continuing aspirin indefinitely for secondary prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Discontinuing clopidogrel in 1 month can be done in case of bare metal stents (BMS) and not DES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> 12 months of DAPT is recommended in patient with ACS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. Aspirin should be continued indefinitely in patients with CAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dual antiplatelet therapy is recommended for at least 6 months after drug-eluting stent placement for treatment of stable angina.</span></span></span></p>",
      "correct_choice_id": 216134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54167,
      "choices": [
        {
          "id": 216137,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Another bolus of atropine </span></span></span></p>"
        },
        {
          "id": 216138,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">IV Norepinephrine </span></span></span></p>"
        },
        {
          "id": 216139,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">IV Dopamine</span></span></span></p>"
        },
        {
          "id": 216140,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Dobutamine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old male with recent post-CABG (coronary artery bypass graft) status presents with chest pain. On arrival, his blood pressure is 60/30 mmHg with a heart rate of 30/min. The ECG shows a narrow complex arrhythmia. The patient has already received three boluses of IV atropine. While awaiting transcutaneous pacing, which of the following is the next appropriate step in management?</span></span></p>",
      "unique_key": "Q2925354",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927036,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) IV Dopamine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is experiencing symptomatic bradycardia (low heart rate) with severe hypotension, likely due to a post-operative complication. The maximum dose of atropine has already been given with no adequate response. The next best step is cardiac pacing. But while awaiting pacing, one can try chronotropic drugs like dopamine, epinephrine in the ER. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Another bolus of atropine:</span></strong><span style=\"font-size:12.0pt\"> As per ACLS guidelines, a maximum of three boluses of atropine are recommended for symptomatic bradycardia. Further doses are unlikely to be effective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IV Norepinephrine:</span></strong><span style=\"font-size:12.0pt\"> While norepinephrine is a potent vasopressor, it can also worsen bradycardia due to its reflex bradycardia effect (baroreceptor response).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Opion D. IV Dobutamine:</span></strong><span style=\"font-size:12.0pt\"> Dobutamine primarily acts on beta-1 receptors, increasing heart rate and contractility, but it can also cause vasodilation (beta-2 effects), potentially worsening hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronotropic drugs like dopamine can be tried while awaiting pacing in symptomatic bradycardia with hypotension, especially when atropine has been ineffective. </span></span></span></p>",
      "correct_choice_id": 216139,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54168,
      "choices": [
        {
          "id": 216141,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac magnetic resonance perfusion scan </span></span></span></p>"
        },
        {
          "id": 216142,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CT angiography </span></span></span></p>"
        },
        {
          "id": 216143,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SPECT MPI </span></span></span></p>"
        },
        {
          "id": 216144,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise echocardiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following non-invasive tests has the best accuracy in detecting coronary stenosis?</span></span></p>",
      "unique_key": "Q5605081",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927037,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Coronary CT angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Accuracy in diagnostic tests is often determined by considering both sensitivity and specificity. Coronary CT angiography is the most accurate as it has the highest sensitivity and specificity. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-091702.png\" style=\"height:355px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CMR perfusion</span></strong><span style=\"font-size:12.0pt\"> have high sensitivity, but their specificity is not as high as Coronary CTA, meaning they might produce more false-positive results.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise echocardiography</span></strong><span style=\"font-size:12.0pt\"> and </span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>C.&nbsp;SPECT MPI</strong> have lower sensitivity and specificity than Coronary CTA, indicating a higher chance of both false negatives and false positives.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CTA is a highly accurate non-invasive test for detecting coronary stenosis due to its excellent sensitivity and specificity. It is a valuable tool for diagnosing and evaluating CAD.</span></span></span></p>",
      "correct_choice_id": 216142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54171,
      "choices": [
        {
          "id": 216153,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenosine 6 mg IV </span></span></span></p>"
        },
        {
          "id": 216154,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carotid body massage </span></span></span></p>"
        },
        {
          "id": 216155,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Metoprolol 5 mg IV </span></span></span></p>"
        },
        {
          "id": 216156,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Valsalva maneuver</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old man with bacterial pneumonia experiences a sudden lightheadedness. His BP is stable, and the rhythm strip is shown. Which of the following is most likely to lead to sustained improvement in heart rate?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-182921.png\" style=\"height:108px; width:400px\" /></span></span></p>",
      "unique_key": "Q6519677",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927038,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Metoprolol 5 mg IV</strong> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has focal atrial tachycardia. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Focal atrial tachycardia (FAT) accounts for ~10% of PSVTs in patients referred for catheter ablation (most common is AVNRT responsible for ~60% of PSVTs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The arrows (which are a nice clue in the question!) indicate the ectopic atrial activity. While one could consider that this might be sinus tachycardia, the rate far exceeds the patient&rsquo;s maximal predicted heart rate (220 &ndash; age) and obviates the possibility of any sinus rhythm. Any maneuver or pharmacologic therapy aimed at producing transient atrioventricular (AV) nodal block (e.g., Valsalva, carotid massage, adenosine) may briefly slow the ventricular response. However, since focal atrial tachycardia does not rely on the AV node for continuation it is rare that transient AV nodal block will terminate the arrhythmia. Beta blockers or non-dihydropyridine calcium channel blockers can lead to sustained improvement in heart rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adenosine 6 mg IV</span></strong><span style=\"font-size:12.0pt\">: Primarily used for supraventricular tachycardia (SVT) and may not be effective in FAT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carotid body massage</span></strong><span style=\"font-size:12.0pt\">: A vagal maneuver that may temporarily slow the heart rate but is not a definitive treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Valsalva maneuver</span></strong><span style=\"font-size:12.0pt\">: A vagal maneuver that may temporarily slow the heart rate but is not a definitive treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Focal atrial tachycardia is not dependent on the AV node and beta-blockers or non-dihydropyridine CCBs are the preferred treatment options for rate control. </span></span></span></p>",
      "correct_choice_id": 216155,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54172,
      "choices": [
        {
          "id": 216157,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium ryanodine receptor </span></span></span></p>"
        },
        {
          "id": 216158,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmosomal proteins </span></span></span></p>"
        },
        {
          "id": 216159,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Potassium channel </span></span></span></p>"
        },
        {
          "id": 216160,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Sarcomere proteins</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You are called to the ER for a young patient in cardiac arrest during exercise. ECG showed bidirectional VT and it was cardioverted immediately. ECG post-cardioversion is normal. 2D Echo and cardiac MRI are also normal. Mutations in which protein are responsible for this?</span></span></p>",
      "unique_key": "Q6165127",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927089,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Calcium ryanodine receptor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s young age, cardiac arrest during exercise (with bidirectional VT), normal resting ECG and normal structural heart on imaging strongly suggest CPVT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Desmosomal proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in desmosomal proteins cause arrhythmogenic right ventricular cardiomyopathy (ARVC), which is a structural heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Potassium channel:</span></strong><span style=\"font-size:12.0pt\"> Mutations in potassium channels can cause long QT syndrome. In this case resting ECG would have showed long QTc. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sarcomere proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in sarcomere proteins cause hypertrophic cardiomyopathy (HCM), which would have resulted in structural heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize bidirectional VT as a hallmark of CPVT, an inherited arrhythmia syndrome caused by mutations in the cardiac ryanodine receptor (RyR2).</span></span></span></p>",
      "correct_choice_id": 216157,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54176,
      "choices": [
        {
          "id": 216173,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Two anginal episode in 24 hours. </span></span></span></p>"
        },
        {
          "id": 216174,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Age. </span></span></span></p>"
        },
        {
          "id": 216175,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daily aspirin use. </span></span></span></p>"
        },
        {
          "id": 216176,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the above confer increased risk.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You are seeing a 75-year-old man admitted for non-ST-elevation myocardial infarction. He has a history of CAD and takes daily aspirin. He&#39;s had multiple angina episodes in the past few days, has ST-segment depression on ECG, and elevated troponin. Which of the following details does NOT confer increased risk of poor outcomes?</span></span></p>",
      "unique_key": "Q2058178",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927090,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) All of the above confer increased risk</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with documented non&ndash;ST-elevation acute coronary syndrome (ACS) exhibit a wide spectrum of early (30 days) risk of death, ranging from 1 to 10%, and a recurrent ACS rate of 5&ndash;15% during the first year. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Assessment of risk can be accomplished by clinical risk scoring systems such as that developed from the Thrombolysis in Myocardial Infarction (TIMI) Trials, which includes seven independent risk factors (age &ge;65 years, 3 or more of the traditional risk factors for CAD, known history of CAD or coronary stenosis &ge; 50%, daily aspirin use in the prior week, more than one anginal episode in the past 24 hours, ST-segment deviation of at least 0.5 mm, and an elevated cardiac specific biomarker above the upper limit of normal). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Additional risk factors include diabetes, LV dysfunction, renal dysfunction, and elevated BNP. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Two anginal episode in 24 hours</span></strong><span style=\"font-size:12.0pt\">: High risk indicating loss of ischemic preconditioning and an active/ongoing ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Age</span></strong><span style=\"font-size:12.0pt\">: Advanced age is the SINGLE most important risk factor in ACS.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Daily aspirin use</span></strong><span style=\"font-size:12.0pt\">: While aspirin is cardioprotective, ACS despite use of aspirin indicates high thrombus burden and hence, high risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TIMI score for NSTE-ACS is important!</span></span></span></p>",
      "correct_choice_id": 216176,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54179,
      "choices": [
        {
          "id": 216185,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ankle-brachial index (ABI) testing </span></span></span></p>"
        },
        {
          "id": 216186,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive angiography </span></span></span></p>"
        },
        {
          "id": 216187,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnetic resonance angiography (MRA) </span></span></span></p>"
        },
        {
          "id": 216188,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Segmental lower extremity blood pressure testing</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with a history of smoking presents with progressive bilateral calf pain that worsens with walking and improves with rest. He has normal resting ankle-brachial index (ABI) values. What is the most appropriate next test?</span></span></p>",
      "unique_key": "Q4735747",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927091,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Exercise ankle-brachial index (ABI) testing</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ABI testing is indicated in patients with normal or borderline resting ABI but with symptoms suggestive of peripheral artery disease (PAD). It can reveal a drop in ABI after exercise, confirming the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Invasive angiography</span></strong><span style=\"font-size:12.0pt\">: Not the initial test, reserved for patients with severe PAD or when revascularization is planned. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MRA</span></strong><span style=\"font-size:12.0pt\">: Another option for anatomic imaging, but exercise ABI is a less invasive first step. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Segmental lower extremity blood pressure testing</span></strong><span style=\"font-size:12.0pt\">: Used to localize PAD, but not necessary as the initial test when the ABI is normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% of patients with typical claudication symptoms have a normal or borderline ankle-brachial index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ABI testing is useful to evaluate for peripheral artery disease in patients with normal ABI values (&gt;0.90 and &le;1.40) and high suspicion of PAD.</span></span></span></p>",
      "correct_choice_id": 216185,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54183,
      "choices": [
        {
          "id": 216201,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atorvastatin </span></span></span></p>"
        },
        {
          "id": 216202,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colestipol </span></span></span></p>"
        },
        {
          "id": 216203,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
        },
        {
          "id": 216204,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Icosapent ethyl</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with peripheral artery disease (PAD) was prescribed atorvastatin. He has read in a newspaper that statins can cause muscle aches and stopped taking atorvastatin after he developed worsening leg pain upon walking. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q1772279",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927092,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Atorvastatin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Statin therapy is crucial for secondary prevention in PAD. Reintroducing atorvastatin with proper education about potential side effects and strategies for management is the best approach. Patients with PAD may confuse symptoms of intermittent claudication with adverse effects of statins (myalgia), which may contribute to the low adherence rate. The most appropriate treatment is patient education and reintroduction of atorvastatin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colestipol</span></strong><span style=\"font-size:12.0pt\"> (bile acid resin): Not a first-line agent for PAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ezetimibe</span></strong><span style=\"font-size:12.0pt\"> (cholesterol absorption inhibitor): Monotherapy with ezetimibe is NOT a substitute for statin therapy. Can be used as an add on if LDL-C is not adequately reduced. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Icosapent ethyl</span></strong><span style=\"font-size:12.0pt\"> (fish oil): Used for triglyceride lowering, which may be considered in addition to statins to lower CV risk (in patients with triglycerides of 135-499 mg/dL). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Peripheral artery disease is considered a clinical atherosclerotic cardiovascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Statin therapy is recommended for secondary prevention of atherosclerotic cardiovascular disease in patients with peripheral artery disease.</span></span></span></p>",
      "correct_choice_id": 216201,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6664,
      "choices": [
        {
          "id": 26625,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atherosclerotic plaque rupture</span></span></span></p>"
        },
        {
          "id": 26626,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy</span></span></span></p>"
        },
        {
          "id": 26627,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection (SCAD) </span></span></span></p>"
        },
        {
          "id": 26628,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress-induced (takotsubo) cardiomyopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman 2 weeks postpartum presents with chest pain, ST-segment elevation in anterior leads, and elevated troponin. She has no risk factors for atherosclerosis. What is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q9616697",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927093,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Spontaneous coronary artery dissection (SCAD)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SCAD is a common cause of myocardial infarction in young women, especially in the peripartum period. The absence of atherosclerotic risk factors and the timing of the event make SCAD the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atherosclerotic plaque rupture</span></strong><span style=\"font-size:12.0pt\">: Unlikely in a young woman with no risk factors. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peripartum cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Presents with heart failure symptoms and global LV dysfunction, not ST-elevation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Takotsubo cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Typically triggered by stress, often presents with apical ballooning on echo. Common in post-menopausal women (not young women).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection is the most common cause of pregnancy-associated myocardial infarction and occurs most commonly in the first month postpartum</span></span></span></p>",
      "correct_choice_id": 26627,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6665,
      "choices": [
        {
          "id": 26629,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intra-aortic balloon pump placement </span></span></span></p>"
        },
        {
          "id": 26630,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous dobutamine </span></span></span></p>"
        },
        {
          "id": 26631,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous 0.9% saline </span></span></span></p>"
        },
        {
          "id": 26632,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral metoprolol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old man presents with a 3-hour history of chest pain. His BP is 80/50 mmHg, HR is 120/min and has elevated JVP and clear lungs. ECG is shown. What is the most appropriate treatment?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-101859.png\" style=\"height:352px; width:400px\" /></span></span></p>",
      "unique_key": "Q6150699",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927094,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Intravenous 0.9% saline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is likely experiencing right ventricular (RV) infarction, a complication of inferior MI. The key features suggestive of RV infarction are hypotension, elevated central venous pressure, clear lungs, and ST-segment elevation in lead V4R. Intravenous fluids are the first-line treatment to increase RV preload and improve cardiac output.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intra-aortic balloon pump</span></strong><span style=\"font-size:12.0pt\">: Indicated in cardiogenic shock with LV dysfunction, but not the first-line treatment for RV infarction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intravenous dobutamine:</span></strong><span style=\"font-size:12.0pt\"> Inotrope may be considered if fluids are ineffective, but not the initial management. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Oral metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blockers can worsen hypotension and should be avoided in RV infarction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with an inferior myocardial infarction with right ventricular involvement and hypotension should receive intravenous fluids.</span></span></span></p>",
      "correct_choice_id": 26631,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6668,
      "choices": [
        {
          "id": 26641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac tamponade </span></span></span></p>"
        },
        {
          "id": 26642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic liver disease </span></span></span></p>"
        },
        {
          "id": 26643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis </span></span></span></p>"
        },
        {
          "id": 26644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrictive cardiomyopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with a history of CABG presents with progressive fatigue, dyspnea, elevated jugular venous pressure with Kussmaul&#39;s sign, and a pericardial knock. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4180215",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927095,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Constrictive pericarditis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of Kussmaul&#39;s sign (lack of decrease or paradoxical increase in JVP during inspiration), pericardial knock, and signs of right heart failure (elevated JVP, edema, ascites) in a patient with prior cardiac surgery strongly suggest constrictive pericarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cardiac tamponade</span></strong><span style=\"font-size:12.0pt\">: Would not present with Kussmaul&#39;s sign or pericardial knock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chronic liver disease</span></strong><span style=\"font-size:12.0pt\">: Can cause ascites and edema but not the other findings. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Restrictive cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Can mimic constrictive pericarditis, but the history of CABG makes the latter more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Kussmaul sign and pericardial knock, if present, are helpful clues to the presence of constrictive pericarditis.</span></span></span></p>",
      "correct_choice_id": 26643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6670,
      "choices": [
        {
          "id": 26649,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
        },
        {
          "id": 26650,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombolysis and admission to a telemetry bed </span></span></span></p>"
        },
        {
          "id": 26651,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombolysis and transfer to a PCI center </span></span></span></p>"
        },
        {
          "id": 26652,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transfer to a tertiary care center</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old man presents with an chest pain, nausea and diaphoresis. ECG is shown. The nearest tertiary care center is 140 minutes away. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-102708.png\" style=\"height:227px; width:400px\" /></span></span></p>",
      "unique_key": "Q4247628",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927096,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Thrombolysis and transfer to a PCI center</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When primary PCI cannot be performed within 120 minutes of first medical contact (FMC), thrombolytic therapy is recommended for STEMI patients. While undergoing thrombolysis, the patient should be transferred to a PCI center for further evaluation and potential rescue PCI if needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT angiography</span></strong><span style=\"font-size:12.0pt\">: Delays reperfusion therapy, which is crucial in STEMI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thrombolyse and admit</span></strong><span style=\"font-size:12.0pt\">: Does not allow for timely angiography and potential rescue PCI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Transfer to tertiary care center</span></strong><span style=\"font-size:12.0pt\">: Delays reperfusion and worsens outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">For patients with STEMI, thrombolytic therapy is recommended if symptom onset is within 12 hours and PPCI is not available within 120 minutes of FMC.</span></span></span></p>",
      "correct_choice_id": 26651,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6673,
      "choices": [
        {
          "id": 26661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atropine </span></span></span></p>"
        },
        {
          "id": 26662,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tenecteplase </span></span></span></p>"
        },
        {
          "id": 26663,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary Angioplasty</span></span></span></p>"
        },
        {
          "id": 26664,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Temporary pacing</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old woman presents with severe chest pain for the last 3 hours. She is diaphoretic and appears drowsy. Her BP is 80/60 mm Hg and PR is 60/min. ECG is shown below. She was started on aspirin, clopidogrel and heparin. What is the next step?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-102907.png\" style=\"height:222px; width:400px\" /></span></span></p>",
      "unique_key": "Q5848565",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927097,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Temporary pacing</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is presenting with an acute anterior MI complicated by cardiogenic shock and high-grade AV block (Mobitz II).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The immediate priority in this situation is to stabilize the patient&#39;s hemodynamic status and address the conduction abnormality. Temporary pacing is the most appropriate next step to provide electrical support and maintain adequate cardiac output until definitive revascularization can be performed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atropine:</span></strong><span style=\"font-size:12.0pt\"> Atropine may be useful for bradycardia but is unlikely to be effective in the setting of high-grade AV block. Additionally, it does not address the underlying myocardial ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tenecteplase:</span></strong><span style=\"font-size:12.0pt\"> While fibrinolysis with tenecteplase may be considered in some STEMI cases, it is not the first-line therapy in this case. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Primary Angioplasty:</span></strong><span style=\"font-size:12.0pt\"> Primary PCI is the preferred reperfusion strategy for STEMI, but it should be performed after stabilizing the patient&#39;s hemodynamics with temporary pacing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anterior<strong> </strong>MI related bradyarrhythmias are inherently unstable and need temporary pacing. </span></span></span></p>",
      "correct_choice_id": 26664,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6675,
      "choices": [
        {
          "id": 26669,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
        },
        {
          "id": 26670,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intra-aortic balloon pump (IABP) placement</span></span></span></p>"
        },
        {
          "id": 26671,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol </span></span></span></p>"
        },
        {
          "id": 26672,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent cardiac transplantation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 71-year-old woman presents with cardiogenic shock. ECG showed ST depressions in multiple leads and her Troponins were elevated. PCI was performed successfully but she continues to be in cardiogenic shock and she is on aspirin, prasugrel and norepinephrine. Which of the following is the most appropriate additional management?</span></span></p>",
      "unique_key": "Q9704389",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927098,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Intra-aortic balloon pump (IABP) placement</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment of cardiogenic shock initially focuses on reversing the cause of shock, such as reperfusion in the setting of acute coronary syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In cardiogenic shock, appropriate therapies to support cardiac output include inotropes, vasopressors, and mechanical support (such as balloon pumps, percutaneous ventricular assist devices, and extracorporeal membrane oxygenation).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin</span></strong><span style=\"font-size:12.0pt\">: Weak inotrope, unlikely to be effective in cardiogenic shock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blocker, contraindicated in cardiogenic shock due to negative inotropic effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Urgent cardiac transplantation</span></strong><span style=\"font-size:12.0pt\">: Not feasible in the acute setting. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IABP is a mechanical circulatory support device that can temporarily improve hemodynamics in patients with cardiogenic shock after MI by reducing afterload and improving coronary perfusion.</span></span></span></p>",
      "correct_choice_id": 26670,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6682,
      "choices": [
        {
          "id": 26697,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus clopidogrel </span></span></span></p>"
        },
        {
          "id": 26698,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus ticagrelor</span></span></span></p>"
        },
        {
          "id": 26699,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus rivaroxaban plus ticagrelor</span></span></span></p>"
        },
        {
          "id": 26700,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rivaroxaban plus ticagrelor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 69-year-old woman with a history of NSTEMI and AF underwent a successful PCI with a drug eluting stent. What is the most appropriate management of her antithrombotic therapy?</span></span></p>",
      "unique_key": "Q3000601",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927099,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Rivaroxaban plus ticagrelor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The AUGUSTUS trial demonstrated that dual therapy with a direct oral anticoagulant (DOAC) like rivaroxaban and a P2Y12 inhibitor like ticagrelor resulted in lower bleeding rates without an increase in ischemic events (when compared with triple therapy - DOAC + aspirin + P2Y12 inhibitor) in patients with atrial fibrillation (AF) undergoing PCI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin plus clopidogrel:</span></strong><span style=\"font-size:12.0pt\"> This is traditional dual antiplatelet therapy (DAPT) and does not address the need for anticoagulation in AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aspirin plus ticagrelor:</span></strong><span style=\"font-size:12.0pt\"> Similar to option a, it lacks anticoagulation for AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Aspirin plus rivaroxaban plus ticagrelor:</span></strong><span style=\"font-size:12.0pt\"> Triple therapy is no longer recommended as it increases bleeding risk without significant additional benefit compared to dual therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Among patients with atrial fibrillation who have undergone percutaneous coronary intervention for acute coronary syndrome, double therapy with clopidogrel or ticagrelor plus a direct oral anticoagulant is recommended over triple therapy with an oral anticoagulant, aspirin, and P2Y12 inhibitor to reduce the risk for bleeding.</span></span></span></p>",
      "correct_choice_id": 26700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6685,
      "choices": [
        {
          "id": 26709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recurrent MI</span></span></span></p>"
        },
        {
          "id": 26710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early Pericarditis</span></span></span></p>"
        },
        {
          "id": 26711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dressler&#39;s Syndrome</span></span></span></p>"
        },
        {
          "id": 26712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe GERD due to aspirin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 51-year-old male presents with chest pain, 4 days after he was diagnosed with an ST elevation myocardial infarction (STEMI). It is severe, central chest pain with radiation to the trapezius and worse with deep inspiration. The pain woke him from sleep and has improved slightly after getting up out of bed. His Troponin levels were unchanged and ECG showed new saddle-shaped ST elevations in inferior and lateral leads. What is the likely cause?</span></span></p>",
      "unique_key": "Q8176879",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927100,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Early Pericarditis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is most consistent with early pericarditis, which is a common complication of STEMI occurring within the first few days after the infarction. The typical features include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Chest pain:</span></strong><span style=\"font-size:12.0pt\"> Sharp, pleuritic (worse with inspiration), and positional (relieved by sitting up or leaning forward).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">ECG changes:</span></strong><span style=\"font-size:12.0pt\"> Diffuse ST-segment elevation with a concave or saddle-shaped morphology.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Unchanged troponin:</span></strong><span style=\"font-size:12.0pt\"> Troponin levels are usually not elevated in pericarditis, as it is an inflammatory process and not a myocardial infarction.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Recurrent MI:</span></strong><span style=\"font-size:12.0pt\"> While possible, the unchanged troponin and the specific characteristics of the chest pain make it less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dressler&#39;s Syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is a post-MI syndrome occurring weeks to months after the infarction, characterized by fever, pericarditis, pleuritis, and leukocytosis. It is too early for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Severe GERD due to aspirin:</span></strong><span style=\"font-size:12.0pt\"> GERD can cause chest pain, but the pain is typically burning and not pleuritic. Additionally, the ECG changes are not consistent with GERD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early pericarditis is a common complication of STEMI that typically occurs in the first week after MI. </span></span></span></p>",
      "correct_choice_id": 26710,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6573,
      "choices": [
        {
          "id": 26261,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart failure </span></span></span></p>"
        },
        {
          "id": 26262,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stent thrombosis </span></span></span></p>"
        },
        {
          "id": 26263,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor side effect </span></span></span></p>"
        },
        {
          "id": 26264,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular septal rupture</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman experiences shortness of breath after a recent MI that was treated with a drug-eluting stent. Her current medications are aspirin, ticagrelor, enalapril, metoprolol, and atorvastatin. Her physical examination, chest X-ray, and ECG are normal. Which of the following is the most likely cause of her dyspnea?</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
      "unique_key": "Q9965554",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927101,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Ticagrelor side effect</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor, a P2Y12 inhibitor used in ACS, is commonly associated with dyspnea as a side effect. Given the normal exam, ECG, and chest X-ray, this is the most likely cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Heart failure</span></strong><span style=\"font-size:12.0pt\">: Unlikely given the normal physical exam and imaging findings. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Stent thrombosis</span></strong><span style=\"font-size:12.0pt\">: Usually presents with acute coronary syndrome symptoms and ECG changes. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ventricular septal rupture</span></strong><span style=\"font-size:12.0pt\">: Rare complication of MI, usually presents with shock and a new murmur.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dyspnea is a well-recognized and often self-limited side effect of ticagrelor therapy.</span></span></span></p>",
      "correct_choice_id": 26263,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6691,
      "choices": [
        {
          "id": 26733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV lidocaine </span></span></span></p>"
        },
        {
          "id": 26734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnesium repletion </span></span></span></p>"
        },
        {
          "id": 26735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol </span></span></span></p>"
        },
        {
          "id": 26736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium repletion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Thiru is admitted after an anterior MI. In the ICU, he has frequent premature ventricular contractions (PVCs) and lab results show S. K of 2.9 mEq/L and S. Mg of 1 mg/dL. Which of the following is NOT indicated in this setting?</span></span></p>",
      "unique_key": "Q2022295",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927102,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) IV lidocaine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute MI, frequent PVCs can be a precursor to ventricular fibrillation. Beta-blockers (metoprolol), and correction of electrolyte imbalances like hypokalemia and hypomagnesemia, are essential in preventing arrhythmias and reducing mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV lidocaine is an antiarrhythmic drug that is not routinely indicated for suppressing PVCs or asymptomatic non-sustained ventricular tachycardia (NSVT) in this setting. It may be considered if sustained VT or ventricular fibrillation occurs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Magnesium repletion</span></strong><span style=\"font-size:12.0pt\">: Indicated to correct hypomagnesemia, which can trigger arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blocker, reduces myocardial oxygen demand and helps prevent arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Potassium repletion</span></strong><span style=\"font-size:12.0pt\">: Indicated to correct hypokalemia, which can also trigger arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers and correction of electrolyte imbalances re essential in preventing arrhythmias and reducing mortality in acute MI. </span></span></span></p>",
      "correct_choice_id": 26733,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6697,
      "choices": [
        {
          "id": 26757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
        },
        {
          "id": 26758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colchicine </span></span></span></p>"
        },
        {
          "id": 26759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids </span></span></span></p>"
        },
        {
          "id": 26760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following medications should be avoided in patients with an acute ST-elevation myocardial infarction?</span></span></span></p>",
      "unique_key": "Q5341502",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927103,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Glucocorticoids</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids and nonsteroidal anti-inflammatory agents, with the exception of aspirin, should be avoided in patients with STSTEMI. They can impair infarct healing and increase the risk of myocardial rupture, and their use may result in a larger infarct scar. In addition, they can increase coronary vascular resistance, thereby potentially reducing flow to ischemic myocardium. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin:</span></strong><span style=\"font-size:12.0pt\"> Aspirin is an antiplatelet medication that is beneficial in STEMI. It helps prevent further clot formation and reduces the risk of complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colchicine:</span></strong><span style=\"font-size:12.0pt\"> Colchicine is an anti-inflammatory medication that can be used in certain cases of pericarditis, but it is not contraindicated in STEMI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoprolol:</span></strong><span style=\"font-size:12.0pt\"> Metoprolol is a beta-blocker that reduces heart rate and blood pressure, decreasing the workload on the heart. It is beneficial in STEMI unless there are specific contraindications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NSAIDs (except aspirin) and glucocorticoids are absolutely C/I in STEMI.</span></span></span></p>",
      "correct_choice_id": 26759,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54189,
      "choices": [
        {
          "id": 216225,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue aspirin, continue clopidogrel, and proceed with cataract surgery. </span></span></span></p>"
        },
        {
          "id": 216226,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel, continue aspirin, and proceed with cataract surgery.</span></span></span></p>"
        },
        {
          "id": 216227,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue both aspirin and clopidogrel and proceed with cataract surgery. </span></span></span></p>"
        },
        {
          "id": 216228,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Postpone the surgery for 6 months.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mrs. Hinduja, a 64-year-old woman, had a drug-eluting (everolimus) stent placed one month ago for a recent MI. She is on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Her ophthalmologist wants to know if these can be stopped for a cataract surgery next week. What is the most appropriate advice?</span></span></p>",
      "unique_key": "Q7148921",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927104,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Postpone the surgery for 6 months.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Percutaneous therapy of CAD underwent a paradigm shift with the introduction of coronary stents in 1994. However, metallic stents are also prone to stent thrombosis (1&ndash;3%), either acute (&lt;24 hours) or subacute (1&ndash;30 days), which can be ameliorated by greater attention to full initial stent deployment and the use of dual antiplatelet therapy (DAPT) (aspirin, plus a platelet P2Y12 receptor blocker [clopidogrel, prasugrel, or ticagrelor]).&nbsp; Late (30 days to 1 year) and very late stent thrombosis (&gt;1 year) occur very infrequently with stents but are slightly more common with first-generation drug-eluting stents, necessitating DAPT for up to 1 year or longer. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Use of the second-generation stents (such as Mrs. Hinduja&rsquo;s everolimus-eluting stent) is associated with lower rates of late and very late stent thrombosis, and shorter durations of DAPT may be possible. Premature discontinuation of DAPT, particularly in the first month after implantation, is associated with a significantly increased risk for stent thrombosis (3&ndash;9&times; greater). Stent thrombosis results in death in 10&ndash;20% and myocardial infarction in 30&ndash;70% of patients. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elective surgery (such as Mrs. Hinduja&rsquo;s cataract removal) that requires discontinuation of antiplatelet therapy after DES implantation should be postponed until after 6 months and preferably after 1 year, if at all possible. At that point, clopidogrel can be reasonably discontinued if no other mitigating factors are present. If at all possible, aspirin should be continued.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue aspirin, continue clopidogrel, and proceed with cataract surgery, Option B. Discontinue clopidogrel, continue aspirin, and proceed with cataract surgery&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option C. Discontinue both aspirin and clopidogrel and proceed with cataract surgery</span></strong><span style=\"font-size:12.0pt\">: Stopping either or both antiplatelet medications prematurely increases the risk of stent thrombosis and is not recommended.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stopping DES in the first 6 months is associated with increased risk of in-stent thrombosis and hence, elective surgeries must be postponed.</span></span></span></p>",
      "correct_choice_id": 216228,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6607,
      "choices": [
        {
          "id": 26397,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add digoxin </span></span></span></p>"
        },
        {
          "id": 26398,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
        },
        {
          "id": 26399,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol dosage </span></span></span></p>"
        },
        {
          "id": 26400,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch lisinopril to valsartan-sacubitril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 67-year-old woman with stable heart failure with reduced ejection fraction (HFrEF) is on maximum doses of lisinopril, among other medications. Which treatment is most appropriate to further reduce HF hospitalizations and mortality?</span></span></span></p>",
      "unique_key": "Q1413244",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927105,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Switch lisinopril to valsartan-sacubitril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril has been shown to significantly reduce mortality and HF hospitalizations in patients with HFrEF compared to ACE inhibitors or ARBs alone. This makes it a preferred treatment option for patients who are already on maximum doses of these medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> While it can reduce HF hospitalizations, it does not improve mortality. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used for patients with HFrEF in sinus rhythm and a high heart rate despite beta-blocker therapy. Not applicable here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increasing carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Might not be tolerated well and has not shown the same mortality benefit as valsartan-sacubitril.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril significantly reduces heart failure hospitalizations and mortality in patients with symptomatic heart failure with reduced ejection fraction and is recommended in preference to an ACE inhibitor or angiotensin receptor blocker.</span></span></span></p>",
      "correct_choice_id": 26400,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6608,
      "choices": [
        {
          "id": 26401,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 26402,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing </span></span></span></p>"
        },
        {
          "id": 26403,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
        },
        {
          "id": 26404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lisinopril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old athlete experiences cardiac arrest during a race and is successfully resuscitated. Resting ECG is shown. Echocardiogram shows normal LV function but RV dilation and dysfunction. What is the most appropriate management before discharge?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-115610.jpg\" style=\"height:207px; width:500px\" /></span></span></p>",
      "unique_key": "Q2742687",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927106,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Implantable cardioverter-defibrillator (ICD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sudden cardiac arrest with &lsquo;&epsilon;&rsquo; wave in ECG and RV dysfunction in echo in young athletes raises suspicion for underlying inherited cardiomyopathies, like arrhythmogenic right ventricular cardiomyopathy (ARVC). An ICD is the most appropriate intervention to prevent sudden cardiac death due to arrhythmias. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone:</span></strong><span style=\"font-size:12.0pt\"> Antiarrhythmic medication, but not as effective as ICD for preventing sudden death. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Genetic testing:</span></strong><span style=\"font-size:12.0pt\"> Important for diagnosis and family screening, but not the immediate priority before discharge.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lisinopril:</span></strong><span style=\"font-size:12.0pt\"> ACE inhibitor for LV dysfunction, not indicated in this case with normal LV function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with sustained ventricular arrhythmias (&gt;30 seconds) or cardiac arrest without a reversible cause have a class 1 recommendation for secondary prevention with implantable cardioverter-defibrillator placement.</span></span></span></p>",
      "correct_choice_id": 26403,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6609,
      "choices": [
        {
          "id": 26405,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac MRI </span></span></p>"
        },
        {
          "id": 26406,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exercise echocardiography </span></span></p>"
        },
        {
          "id": 26407,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right and left heart catheterization </span></span></p>"
        },
        {
          "id": 26408,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum &alpha;-galactosidase level</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with ascites, pedal edema and elevated JVP. ECG showed low voltage complexes and echo showed increased LV wall thickness. He also has a history of carpal tunnel syndrome. What is the most appropriate test?</span></span></p>",
      "unique_key": "Q2768512",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927107,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Cardiac MRI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of heart failure, increased wall thickness, low voltage on ECG, and carpal tunnel syndrome raises suspicion for infiltrative cardiomyopathy, like transthyretin amyloid (ATTR) amyloidosis. CMR with gadolinium is the most sensitive and specific test for diagnosing cardiac amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise echocardiography:</span></strong><span style=\"font-size:12.0pt\"> Primarily used to diagnose coronary artery disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Right and left heart catheterization:</span></strong><span style=\"font-size:12.0pt\"> Invasive and not the first-line test for infiltrative cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum &alpha;-galactosidase level:</span></strong><span style=\"font-size:12.0pt\"> Used to diagnose Fabry disease, which usually causes Hypertrophic Cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac magnetic resonance imaging with gadolinium is highly sensitive and specific for cardiac amyloidosis, but it does not distinguish between AL (immunoglobulin light-chain) amyloidosis and transthyretin amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with cardiac magnetic resonance imaging findings consistent with cardiac amyloidosis, an abnormal 99m-technetium pyrophosphate scan would confirm transthyretin amyloidosis without the need for a biopsy.</span></span></p>",
      "correct_choice_id": 26405,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6611,
      "choices": [
        {
          "id": 26413,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute pulmonary embolism</span></span></span></p>"
        },
        {
          "id": 26414,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascending aortic dissection </span></span></span></p>"
        },
        {
          "id": 26415,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy </span></span></span></p>"
        },
        {
          "id": 26416,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 8-day postpartum woman presents with acute heart failure symptoms. Echocardiogram shows LV dilation and hypokinesis with an ejection fraction of 38%.RV is normal. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8366476",
      "question_audio": null,
      "question_video": null,
      "map_id": 15927108,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Peripartum cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy is characterized by the development of heart failure in the last month of pregnancy or within 5 months postpartum. The presentation of LV dysfunction with no other identifiable cause fits this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute pulmonary embolism</span></strong><span style=\"font-size:12.0pt\">: Less likely given normal right heart function on echocardiogram. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Ascending aortic dissection:</strong> Usually presents with acute chest pain, and echo would show aortic abnormalities. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Spontaneous coronary artery dissection:</strong> Typically presents with chest pain and ECG changes indicative of ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripartum cardiomyopathy is left ventricular systolic dysfunction with onset toward the end of pregnancy or in the months after delivery in the absence of another identifiable cause; patients often present with features of heart failure.</span></span></p>",
      "correct_choice_id": 26415,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}